SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused
on metabolic and endocrine disorders, today announced that the
Company will present at the Raymond James Human Health Innovation
Conference. The conference will be held virtually.
Presentation details are below.
Raymond James Human Health Innovation Conference
June 21-23
Presentation time:
June 21, 2021 starting at 12:40 PM
ET
Webcast link:
https://kvgo.com/rj-health/lipocine-inc-june-2021
The webcast of this presentation will also be available on
Lipocine's corporate website under "Events & Presentations" in
the Investors section.
About Lipocine Inc.
Lipocine Inc. is a clinical-stage
biopharmaceutical company focused on metabolic and endocrine
disorders using its proprietary drug delivery technologies.
Lipocine's clinical development pipeline includes: TLANDO, LPCN
1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107. TLANDO, a
novel oral prodrug of testosterone containing testosterone
undecanoate, has received tentative approval from the FDA for
conditions associated with a deficiency of endogenous testosterone,
also known as hypogonadism, in adult males. LPCN 1144, an oral
prodrug of bioidentical testosterone, recently completed a
proof-of-concept clinical study demonstrating the potential utility
in the treatment of non-cirrhotic NASH. LPCN 1144 is currently
being studied in a Phase 2 clinical study. TLANDO XR, a novel
oral prodrug of testosterone, originated and is being developed by
Lipocine as a next-generation oral testosterone product with
potential for once-daily dosing. In a phase 2 clinical evaluation
when administered as once daily or twice daily TLANDO XR met the
typical primary and secondary end points. LPCN 1148 is an oral
prodrug of bioidentical testosterone targeted for the treatment of
cirrhosis. LPCN 1107 is potentially the first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth and has been granted orphan
drug designation by the FDA. LPCN 1154 is an oral neuro-steroid
targeted for the treatment of post-partum depression. For
more information, please visit www.lipocine.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-raymond-james-human-health-innovation-conference-301313327.html
SOURCE Lipocine Inc.